Economic Assessment of High-Dose Versus Adjuvanted Influenza Vaccine: An Evaluation of Hospitalization Costs Based on a Cohort Study

Two influenza vaccines are licensed in the U.S. exclusively for the 65 years and older population: a trivalent inactivated high-dose influenza vaccine (HD-IIV3) and a trivalent inactivated adjuvanted influenza vaccine (aIIV3). In a recent publication, we estimated a relative vaccine effectiveness (r...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Robertus van Aalst, Stefan Gravenstein, Vincent Mor, Salaheddin M. Mahmud, Jan Wilschut, Maarten Postma, Ayman Chit
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-09-01
coleção:	Vaccines
Assuntos:	high-dose adjuvanted aIIV3 HD-IIV3 influenza vaccine economic assessment
Acesso em linha:	https://www.mdpi.com/2076-393X/9/10/1065
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!